Awotiwon Ajibola A, Oduwole Olabisi, Sinha Anju, Okwundu Charles I
Department of Community Health, Faculty of Health Sciences, Stellenbosch University, Cape Town, Western Cape, South Africa.
Cochrane Database Syst Rev. 2015 Mar 20(3):CD011177. doi: 10.1002/14651858.CD011177.pub2.
Measles is still an important cause of childhood morbidity and mortality globally, despite increasing vaccine coverage. Zinc plays a significant role in the maintenance of normal immunological functions, therefore supplements given to zinc-deficient children will increase the availability of zinc and could reduce measles-related morbidity and mortality.
To assess the effects of zinc supplementation in reducing morbidity and mortality in children with measles.
We searched CENTRAL (2014, Issue 5), MEDLINE (1946 to June week 3, 2014), EMBASE (1974 to June 2014), CINAHL (1981 to June 2014), LILACS (1982 to June 2014), Web of Science (1985 to June 2014) and BIOSIS Previews (1985 to June 2014). We also searched ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) to identify unpublished and ongoing studies.
Randomised controlled trials (RCTs) and quasi-RCTs evaluating the effects of zinc in reducing morbidity and mortality in children with measles.
Two review authors independently assessed the studies for inclusion and extracted data on outcomes, details of the interventions and other study characteristics using a standardised data extraction form. We used the risk ratio (RR) and hazard ratio as measures of effect with 95% confidence intervals (CI). We included only one study and we did not conduct any meta-analysis.
One RCT met our inclusion criteria. The study was conducted in India and included 85 children diagnosed with measles and pneumonia. The trial showed that there was no significant difference in mortality between the two groups (risk ratio (RR) 0.34, 95% confidence interval (CI) 0.01 to 8.14). Also, there was no significant difference in time to absence of fever between the two groups (hazard ratio (HR) 1.08, 95% CI 0.67 to 1.74). No treatment-related side effects were reported in either group. The overall quality of the evidence can be described as very low.
AUTHORS' CONCLUSIONS: We cannot draw any definite conclusions from this review about the effects of zinc supplementation on clinical outcomes of children with measles due to the very low quality of the evidence available. There is insufficient evidence to confirm or refute the effect of zinc supplementation in measles.
尽管疫苗接种覆盖率不断提高,但麻疹仍是全球儿童发病和死亡的重要原因。锌在维持正常免疫功能方面发挥着重要作用,因此给缺锌儿童补充锌将增加锌的可利用性,并可能降低与麻疹相关的发病率和死亡率。
评估补充锌对降低麻疹患儿发病率和死亡率的影响。
我们检索了考克兰系统评价数据库(CENTRAL,2014年第5期)、医学文献数据库(MEDLINE,1946年至2014年6月第3周)、荷兰医学文摘数据库(EMBASE,1974年至2014年6月)、护理学与健康领域数据库(CINAHL,1981年至2014年6月)、拉丁美洲和加勒比地区健康科学数据库(LILACS,1982年至2014年6月)、科学引文索引扩展版(Web of Science,1985年至2014年6月)和生物学文摘数据库(BIOSIS Previews,1985年至2014年6月)。我们还检索了美国国立医学图书馆临床试验注册库(ClinicalTrials.gov)和世界卫生组织(WHO)国际临床试验注册平台(ICTRP),以识别未发表和正在进行的研究。
评估锌对降低麻疹患儿发病率和死亡率影响的随机对照试验(RCT)和半随机对照试验(quasi-RCT)。
两位综述作者独立评估纳入研究,并使用标准化数据提取表提取有关结局、干预措施细节和其他研究特征的数据。我们使用风险比(RR)和风险比作为效应量度,并给出95%置信区间(CI)。我们仅纳入了一项研究,未进行任何荟萃分析。
一项RCT符合我们的纳入标准。该研究在印度进行,纳入了85名被诊断为麻疹和肺炎的儿童。试验表明,两组之间的死亡率无显著差异(风险比(RR)0.34,95%置信区间(CI)0.01至8.14)。此外,两组之间退热时间也无显著差异(风险比(HR)1.08,95%CI 0.67至1.74)。两组均未报告与治疗相关的副作用。证据的总体质量可描述为极低。
由于现有证据质量极低,我们无法从本综述中就补充锌对麻疹患儿临床结局的影响得出任何明确结论。没有足够的证据证实或反驳补充锌在麻疹中的作用。